Advertisement
Advertisement
ATOS
Atossa Therapeutics, Inc. Common Stock
5.30
USDSponsored
-0.03
-0.47%
Feb 06, 15:59 UTC -5
Closed
After-Market
5.37
+0.06
+1.13%
ATOS Earnings Reports
Positive Surprise Ratio
ATOS beat 20 of 31 last estimates.
65%
Next Report
Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.02
Implied change from Q3 25 (Revenue/ EPS)
--
/-2.86%
Implied change from Q4 24 (Revenue/ EPS)
--
/+1940.00%
Atossa Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, ATOS reported earnings of -1.05 USD per share (EPS) for Q3 25, missing the estimate of -1.02 USD, resulting in a -2.93% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -1.02 USD, with revenue projected to reach -- USD, implying an decrease of -2.86% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Thermo Fisher Scientific, Inc.
Report Date
Jan 29, 2026 For Q4 25
Estimate
$6.51
Actual
$6.57
Surprise
+0.91%
Idexx Laboratories Inc
Report Date
Feb 02, 2026 For Q4 25
Estimate
$2.98
Actual
$3.08
Surprise
+3.12%
IQVIA Holdings Inc.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$3.43
Actual
$3.42
Surprise
-0.34%
Mettler-Toledo International
Report Date
Feb 05, 2026 For Q4 25
Estimate
$12.92
Actual
$13.36
Surprise
+3.34%
STERIS plc
Report Date
Feb 04, 2026 For Q3 26
Estimate
$2.55
Actual
$2.52
Surprise
-0.99%
Hologic Inc
Report Date
Jan 29, 2026 For Q1 26
Estimate
$1.11
Actual
$1.04
Surprise
-6.45%
Mesa Laboratories Inc
Report Date
Feb 03, 2026 For Q3 26
Estimate
$0.28
Actual
$3.07
Surprise
+987.88%
Accuray Incorporated
Report Date
Feb 04, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+1.96%
FAQ
What were Atossa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$1.05, missing estimates by -2.93%, and revenue of $0.00, 0% as expectations.
How did the market react to Atossa Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.74%, changed from $0.83 before the earnings release to $0.81 the day after.
When is Atossa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Atossa Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$1.02 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement